Develop a macrofilaricide candidate for filarial diseases.
current phase of drug development
updated 29 Feb 2020
Following a drug repurposing strategy, screening of compounds against Onchocerca guttura and Onchocerca lienalis identified several candidates from compound libraries provided by pharmaceutical companies. These compound collections are well-characterized chemical series which have been extensively optimized for use in other indications. Although the project was quite successful, none of the identified candidates had a drug profile with utility for filarial diseases. Screening of several more companies yielded further candidates. With funding from the Bill & Melinda Gates Foundation, these companies are conducting a hit-to-lead and lead optimization programme, which aims to develop a drug candidate for filarial indications. DNDi has contributed to this effort by providing biological resources, expertise, and the target product profile to select the best candidates.
Get our latest news, personal stories, research articles, and job opportunities.